Rie Schultz Hansen, PhD

Rie joined Augustine as CSO in May 2025. With more than 20 years’ experience in drug discovery and early-stage drug development, she is an experienced executive with a strong background in cardio-metabolic and inflammation-driven diseases as well as peptide therapeutics. Prior to joining Augustine, she served as the Chief Scientific Officer at Aelin Therapeutics, where she played a key role in developing a degrader platform based on induced protein aggregation to neutralize disease-causing proteins. Later, she spearheaded an entrepreneurial initiative advancing AI/ML-based solutions derived from Aelin Therapeutics technology. Rie spent the majority of her career at the peptide development specialist Zealand Pharma (CPH: ZEAL) where she worked across multiple functional areas, mainly focused on cardiovascular, metabolic and inflammatory diseases. She received her Master's in Biology and PhD at the Faculty of Medicine, University of Copenhagen. She is also a board member of the Peptide Therapeutics Foundation and a member of the DCAcademy Grant Committee (University of Copenhagen) and obtained her post doctorate in cardiovascular research.